Rapid Trabecular Bone Loss After Cardiac Transplantation Using FK506 (Tacrolimus)-Based Immunosuppression
H.U. Stempfle, C. Werner, S. Echtler, T. Assum, B. Meiser, C.E. Angermann, K. Theisen, and R. Ga¨rtner
THE MACROLIDE lactone tacrolimus (FK506) is a P Ͻ .01). No fracture was documented. There were no
new immunosuppressive drug that has demonstrated
significant differences in biochemical parameters of calcium
to be 10 to 100 times more potent than cyclosporine A.
metabolism, intact PTH, gonadotropins, and renal function
After forming a complex with the immunophilin FK506-
before and shortly after HTx. Testosterone levels decreased
binding protein, the complex acts in a similar fashion to the
in five of six male patients, with an average of 1.7 ng/mL
cyclosporine-immunophilin complex, resulting in an inhibi-
(range 0.08 to 5.22 ng/mL). One patient became hypogo-
tion of calcineurin, a calcium-dependent serine/threonine
nadal after HTx. Luteinizing hormone increased signifi-
protein phosphatase. This inhibition prevents the assembly
cantly within the normal range from 3.4 Ϯ 0.9 mU/mL to
of the functional transcription of interleukin 2. Although
6.2 Ϯ 1.5 mU/mL (P Ͻ .001). Follicle stimulating hormone
tacrolimus has reputedly less severe side effects, recent
remained unchanged within the normal range.
experimental studies have demonstrated an increase of
bone formation and bone resorption, accompanied by a
significant reduction in percent trabecular area.1 The
present study was undertaken to assess the effects of
tacrolimus-based immunosuppression on bone mineral me-
Despite preexisting reduced bone density, these preliminary
tabolism after orthotopic heart transplantation.
data demonstrated a rapid further reduction on bonemineral density due to a tacrolimus-based immunosuppres-sive regimen that may lead to future fractures. The precise
mechanisms on bone mineral metabolism of each individual
Seven patients (six male, one female; mean age: 51 Ϯ 10 yrs) were
immunosuppressive agent are difficult to examine because
studied before and 3 Ϯ 2 months after heart transplantation (HTx)
of the combination therapy in clinical settings. Besides the
to evaluate the immediate effects of tacrolimus-based immunosup-
well-known negative effects of steroids on bone mineral
pression on bone density, fracture rate, and disturbances in bio-chemical markers. Time interval between both examinations was
metabolism, tacrolimus may have a direct toxic effect on
9 Ϯ 2 months. Aside from FK506 (mean blood level 13 to 18
bone cells and the secretion of local autocrine factors.
ng/mL, radioimmunoassay), immunosuppressive regimen included
Second, the agent may have indirect effects on bone via a
modulation of cytokines and gonadal dysfunction.
Bone mineral density (BMD, g/cm2) was measured at the lumbar
The role of tacrolimus on steroidogenesis of Leydig cells
spine (L2–L4) using dual-energy x-ray absorptiometry (DEXA,
is still controversal. Eighty percent of our study population
Lunar Expert-XL, Madison, Wisc). Vertebral bone density (VBD)
showed a decrease of testosterone levels, which may con-
was evaluated by single energy computer tomography after HTx.
tribute to trabecular bone loss. There was only a slight
Results were expressed as VBD values ϮSD, BMD T-values Ϯ SD,
increase in lutenizing hormone levels, which might be due
and as percentage of variation from baseline. Vertebral fractures
to only one hypogonadal patient. These results are in
were assessed by x-rays of chest, thoracic, and lumbar spine.
Biochemical markers included gonadal hormones, gonadotro-
contrast to experimental data by Tai et al who found no
pins, urinary and serum parameters of calcium metabolism, intact
direct inhibitory effect of tacrolimus on testosterone biosyn-
PTH, 25OHD, and renal function. Data were compared between
thesis in rat Leydig cells.2 Cyclosporine A, with its similar
consecutive measurements as well as to age-matched controls.
From the Division of Cardiology, Division of Endocrinology,
All patients showed significantly impaired bone mineral
and Department of Cardiovascular Surgery, Ludwig-Maximilians
density before transplantation (Ϫ1.3 Ϯ 0.7 g/cm2; 87 Ϯ 7%)
This investigation was supported by a Grant awarded by the
compared to normals. After HTx a further decline in BMD
Ernst und Berta Grimmke Research Foundation.
(Ϫ1.6 Ϯ 0.7 g/cm2; 84 Ϯ 7%) was seen within an average of
Address reprint requests to Dr H.U. Stempfle, Division of
3.1 Ϯ 1.6 months. VBD was also significantly decreased
Cardiology, Medizinische Klinik, Klinikum Innenstadt, LMU
after HTx (75 Ϯ 29 mg/ccm versus 125 Ϯ 25 mg/ccm,
Mu¨nchen, Ziemssenstr. 1, 80336 Mu¨nchen, Germany.
655 Avenue of the Americas, New York, NY 10010
Transplantation Proceedings, 30, 1132–1133 (1998)
TRABECULAR BONE LOSS AFTER TRANSPLANT USING FK506
biologic action, also impairs testicular steroidogenesis and
spermatogenesis in rats3 and humans4 mediated through
1. Cvetkovic M, Mann GN, Romero DF, et al: Transplantation
the hypothalamic-pituitary axis and direct inhibition of
2. Tai J, Tze WT, Murase N, et al: Metabolism 43:533, 1994
In summary, these preliminary data in patients with
3. Seethalakshmi L, Flores C, Malhotra RK, et al: Transplanta-
tacrolimus-based immunosuppression indicate the necessity
to monitor carefully bone mineral metabolism and to
4. Stempfle HU, Ellinger M, Angermann CE, et al: J Am Coll
administer a therapy to prevent further bone loss.
PATIENT INFORMATION PROVERA® ( medroxyprogesterone acetate tablets, USP) Read this PATIENT INFORMATION before you start taking PROVERA and read the patient information each time you refill your PROVERA prescription. There may be new information. This information does not take the place of talking to your health care provider about your medical condition or your treatment. WHAT IS T
Simulations Focus on Package Usability • Industry News – Pharmaceutical & Medical Packaging News – November 2010 In October, Michigan State University (MSU) and Oliver-Tolas Healthcare Packaging debuted their new program, the Healthcare Packaging Immersion Experience (HcPIE). The event brought together healthcare professionals, medical packaging experts from Oliver-Tolas and MSU